Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 5
2004 2
2005 2
2008 1
2009 5
2010 9
2011 4
2012 3
2013 3
2014 4
2015 7
2016 9
2017 9
2018 22
2019 16
2020 14
2021 15
2022 10
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean liang ping xia (73 results)?
ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy.
Wang C, Huang M, Lin Y, Zhang Y, Pan J, Jiang C, Cheng M, Li S, He W, Li Z, Tu Z, Fan J, Zeng H, Lin J, Wang Y, Yao N, Liu T, Qi Q, Liu X, Zhang Z, Chen M, Xia L, Zhang D, Ye W. Wang C, et al. Among authors: xia l. Nat Metab. 2023 Oct;5(10):1765-1786. doi: 10.1038/s42255-023-00883-y. Epub 2023 Sep 4. Nat Metab. 2023. PMID: 37667133
Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients.
Wang D, Qiu B, Liu Q, Xia L, Liu S, Zheng C, Liu H, Mo Y, Zhang X, Hu Y, Zheng S, Zhou Y, Fu J, Chen N, Liu F, Zhou R, Guo J, Fan W, Liu H. Wang D, et al. Among authors: xia l. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3400-3413. doi: 10.1007/s00259-023-06298-x. Epub 2023 Jun 13. Eur J Nucl Med Mol Imaging. 2023. PMID: 37310427
The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Tang LQ, Li XY, Li ZM, Liu ZG, Lin MZ, Zhou H, Yu QW, Zhou J, Zhao C, Chen ZB, Wang XC, Peng JY, Chen QY, Fang WF, Yang YP, Zhang B, Xia LP, Hu PL, Hu WH, Li YJ, Mai HQ, Cai XY. Tang LQ, et al. BMC Med. 2023 Mar 16;21(1):94. doi: 10.1186/s12916-023-02790-1. BMC Med. 2023. PMID: 36927541 Free PMC article. Clinical Trial.
141 results